Preimplantation Genetic Testing utilizes genetic diagnosis methods to enable early detection of genetic defects during IVF treatment to select healthy embryos for implantation.
Rising acceptance and use of IVF treatments by couples and the increased need for advanced genetic diagnosis for diseases in children are enabling the rise of the preimplantation genetic testing market.
The global market for preimplantation genetic testing will most likely expand at over 9% between 2023 to 2032.
The global preimplantation genetic testing market size was estimated to be US$ 504 Million in 2021.
Based on technology, the preimplantation genetic testing market is segmented into Next-Generation Sequencing, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism, Validation Biomarkers, Fluorescence in Situ Hybridization and Polymerase Chain Reaction.
Illumina, Inc., Abbott Laboratories, Agilent Technologies, Inc., PerkinElmer, Inc., Oxford Gene Technology, Yikon Genomics, and SciGene Corporations are some of the companies that are currently leading the preimplantation genetic testing market.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved